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There are a number offactors (planning, process optimization,
organizational structure, people development and the need to see the
total picture) that must be in placefor automation to be as effective
as possible. This paper discusses these factors and their relation-
ship with automation. It evaluates less obvious areas associated
with automation, as well as the more established ones, and
discusses the premise that it is the integration of all these aspects
that truly offers the biggest opportunities.
Introduction
Over the last few years, the pharmaceutical industry has
steadily become more competitive. Clear evidence of this
is seen in the number of mergers and takeovers that have
occurred in the last five to seven years. There is no reason
to assume that this state of affairs will get anything but
worse as we approach the next millennium. For com-
panies to be successful, they need a source of break-
through molecular entities, and a development process
that permits the drug to move effectively from discovery
through IND to NDA or equivalent.
Thus, many companies are re-engineering their develop-
ment processes to achieve the latter and give them a
competitive edge. These processes must be able to sig-
nificantly reduce the development time, for example by
25-30%, while, at the very least, maintaining quality.
They must be achieved without a burnout of staff, an
event which unfortunately is becoming steadily more
common in the industry.
To further exacerbate the problems, the complexity of
the development process significantly increases each year,
as do the registration requirements around the world. In
the Chemistry, Manufacturing and Controls (CMC)
area, the advent of ICH, SUPAC, PAIs, etc. have
significantly changed the ways things are done, with far
more planning and internal controls being applied. In
the author’s department, the concept of ’Good Scientific
Practices’ has been introduced to define all work outside
GMP and GLP.
Finally, global integration is now essential for companies
to be successful.
Processes
The processes involved in developing a medicine from the
glint in a chemist’s eye through to launch are extremely
complicated. Even restricting these to the CMC areas,
they are still immensely complex. Partly as a result of
that, and partly as a result of the way many of the
processes have evolved, they are generally very ineffi-
cient.
A number of years ago, the author’s previous company
went through a major re-engineering exercise to reduce
the time from IND to NDA. It was quickly decided that
development time could be reduced by 50%. While this
may not be possible across the board, it is likely that
savings of 25-30% should be readily realized. So how do
you achieve such process improvements?
First, question everything. There must be no sacred cows,
and re-engineering is not for the faint-hearted. Then,
prepare a flow diagram ofhow things really happen. This
is often a real eye-opener with many processes going
round and round in never-ending loops. Finally, get a
completely clean piece of paper and design it from
scratch as if you were a start-up company. This then
brings you to the hardest part, implementation. The only
advice here is do not give up. You will be very tempted
to, as the revamped processes will probably be worse in
the beginning and you will be surrounded by a lot of
unhappy staff. Perservere, it will take time. Most of the
re-engineering exercises that fail are because they were
not seen through to completion.
Planning
Planning is very important. For plans to work, they must
include key performance indicators so that it can be
determined whether a company is on plan or not. It also
requires training. Training should be taken into teams on
a just-in-time basis and should ask and answer the
questions:
Is the team on track?
How do they know they are on track?
How do they stay on track?
How do they get back on track?
This kind of training has been shown to significantly
increase work without any staff burnout.
In many instances, it has been assumed that automation
and computerization, the ’magic black box’, can solve
these problems. This paper proposes the hypothesis that
automation alone will not provide the necessary improve-
ments: indeed, such an approach may result in a de-
creased efficiency. It then reviews some of the factors
contributing to the successful acceleration of the devel-
opment process and evaluates the role of automation as
an integral part of that accelerated process.
Organizational structure
Many companies make the mistake of designing their
organizational structure and then designing the process
to fit the organizational structure. The opposite is the
way to efficiency. Since so much of the business in the
pharmaceutical industry is cross-functional, then the
organizational structure should be primarily cross-func-
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tional. The greatest opportunities for improved efficiency
are often not in how well a chemist analyses a sample or a
formulator formulates a product, but, rather, in how well
they interact with each other.
Real progress can be made at cross-functional interfaces.
In my present company, we organized by setting up a
number of project teams, which were essentially designed
to be akin to small start-up companies. The teams would
be fully accountable for the running of that project. Such
an organization has two basic problems to overcome. The
first is how to avoid reinventing the wheel for each new
project. The second is how to stop the perception that
staff will not have a job when the project finishes. Centres
of Excellence were created which acted as ’homes’ for
people waiting to be assigned or reassigned to projects. In
reality, these waiting periods were non-existent, but the
centres provided a perceived safety net. In addition, a
small core of people were kept in the centres. Their job
was to set standards across the projects, define process
improvements to improve project team effectiveness, and
provide experts and mentors to the teams, i.e. to have the
time and focus to implement the improvements that
everybody knows need to be done, but nobody has the
time to do.
Technology
What has all this to do with automation? In far too many
instances, there is a perception that there is a ’black box’
answer to all our problems, a perception that we will
develop a system and all that will be needed is to simply
press a button. Technology can do much to support and
facilitate improvement programmes, but, in itself, it does
not solve them. Without good processes, well-designed
and well-executed plans, supported by the correct organ-
izational structure, it is simply the inefficient that is
automated.
In our organization, we include a number of activities
under the umbrella of automation. These include ro-
botics, laboratory acquisition systems, laboratory man-
agement systems, and document management systems.
The primary product that research and development
manufactures is information, often in the form of docu-
ments. If information and documentation are effectively
managed, then projects will also be effectively managed.
Thus, robotic systems, laboratory acqusition and man-
agement systems, etc. must be integrated in a cross-
functional manner with document management systems
to form an overall comprehensive system. Too often, they
exist as separate islands of technology. To achieve this
integration, an overall strategic plan has to be developed
and then peeled like an onion with increasing detail at
each stage. If the plan is not integrated, there is a real
danger of simply shifting the bottlenecks, rather than
achieving real progress.
The other major issue with technology development is
the ’creeping sophistication syndrome’. Here, the system
has more and more refinements planned and developed.
The result is that it is never finished and never becomes
fully operational.
People
Since people are our most valuable resources, it is
interesting to consider the effects of automation on them.
Automation properly developed undoubtedly improves
both consistency and productivity. There is a perception,
however, that it decreases flexibility and innovation. The
errors in this perception should be pointed out to the
people involved very early in the process. Technology
should be used to automate the results of innovation.
Receptor screening is a good example of this. We should,
however, also innovate the results of automation. Com-
binatorial chemistry is a classic example of this, where the
creation of huge numbers of new molecules greatly
increases the innovative opportunities, both in the dis-
covery of new drugs and in the improvement of existing
drugs. However, automation should not be allowed to
stifle personal creativity--major discovery breakthroughs
are still more likely to come from personal ideas. Such
free thinking must be encouraged and automation used
to improve its implementation.
Automation should be used to reduce bureaucracy. Here,
the machines can be regulated rather than the people;
people can be freed from repetitive jobs, which they are
not usually very good at, to increase their innovative
abilities.
Conclusion
Automation can undoubtedly increase the efficiency of a
process, be it a simple single process or a complex
interaction of processes like those related to drug devel-
opment. For automation to be fully effective, it needs to
be part of an overall integrated system that also includes
process improvement, management systems, organiza-
tional structure, and even a belief and culture that
optimizes those opportunities provided by automation.
Great strides have been made in the technology related to
automation. I believe the biggest challenge we now face
is in its integration. Automation improves efficiency, but
we need to ensure it also optimizes effectiveness.
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